Downregulation of thymosin β4 expression by androgen in prostate cancer LNCaP cells

Journal of Andrology

Volumn 29, Issue 2, 2008, Pages 207-212

  Iguchi, Kazuhiro ^a   Ito, Mai ^a   Usui, Shigeyuki ^a   Mizokami, Atsushi ^b   Namiki, Mikio ^b   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Androgen ablation therapy; Androgen receptor

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; THYMOSIN BETA4; ANILIDE; MESSENGER RNA; NITRILE; THYMOSIN; THYMOSIN BETA(4); TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; DOWN REGULATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; CELL CULTURE; DISEASE COURSE; GENETICS; MALE; METABOLISM; PROSTATE TUMOR;

ANDROGENS; ANILIDES; DIHYDROTESTOSTERONE; DISEASE PROGRESSION; DOWN-REGULATION; HUMANS; MALE; NITRILES; PROSTATIC NEOPLASMS; RNA, MESSENGER; THYMOSIN; TOSYL COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 40449111936     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.003608     Document Type: Article

References (32)

1. Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432:466-472.
2. Bokar JA, Roesler WJ, Vandenbark GR, Kaetzel DM, Hanson RW, Nilson JH. Characterization of the cAMP responsive elements from the genes for the alpha-subunit of glycoprotein hormones and phosphoenolpyruvate carboxykinase (GTP). Conserved features of nuclear protein binding between tissues and species. J Biol Chem. 1988;263:19740-19747.
3. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin β4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95:1674-1680.
4. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol. 2004;204:159-166.
5. Emmett JL, Greene LF, Papantoniou A. Endocrine therapy in carcinoma of the prostate gland: 10-year survival studies. J Urol. 1960;83:471-184.
6. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem. 1998;273:31853-31859.
7. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res. 1999;5:2891-2898.
8. Goldstein AL. Thymosin β4: a new molecular target for antitumor strategies. J Natl Cancer Inst. 2003;95:1646-1647.
9. Hsiao HL, Wang WS, Chen PM, Su Y. Overexpression of thymosin β4 renders SW480 colon carcinoma cells more resistant to apoptosis triggered by FasL and two topoisomerase II inhibitors via downregulating Fas and upregulating Survivin expression, respectively. Carcinogenesis. 2006;27:936-944.
10. Huggins C, Hodges CV. Studies on prostatic cancer. I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
11. Iguchi K, Ishii K, Nakano T, Otsuka T, Usui S, Sugimura Y, Hirano K. Isolation and characterization of LNCaP sublines differing in hormone-sensitivity. J Androl. 2007;28:670-678.
12. Iguchi K, Matsunaga S, Nakano T, Usui S, Hirano K. Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells. Anticancer Res. 2006;26:2977-2981.
13. Iguchi K, Usami Y, Hirano K, Hamatake M, Shibata M, Ishida R. Decreased thymosin β4 in apoptosis induced by a variety of antitumor drugs. Biochem Pharmacol. 1999;57:1105-1111.
14. Isaacs JT. New strategies for the medical treatment of prostate cancer. BJU Int. 2005;96(suppl)2:35-40.
15. Jain AK, Moore SM, Yamaguchi K, Eling TE, Baek SJ. Selective nonsteroidal anti-inflammatory drugs induce thymosin β4 and alter actin cytoskeletal organization in human colorectal cancer cells. J Pharmacol Exp Ther. 2004;311:885-891.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
17. Kobayashi T, Okada F, Fujii N, Tomita N, Ito S, Tazawa H, Aoyama T, Choi SK, Shibata T, Fujita H, Hosokawa M. Thymosin-β4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. Am J Pathol. 2002;160:869-882.
18. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78:1162-1166.
19. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin β4 accelerates wound healing. J Invest Dermatol. 1999;113:364-368.
20. Nelson CC, Hendy SC, Shukin RJ, Cheng H, Bruchovsky N, Koop BF, Rennie PS. Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: evidence for differential steroid receptor response elements. Mol Endocrinol. 1999;13:2090-2107.
21. Otto AM, Muller CS, Huff T, Hannappel E. Chemotherapeutic drugs change actin skeleton organization and the expression of β-thymosins in human breast cancer cells. J Cancer Res Clin Oncol. 2002;128:247-256.
22. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin β4 promotes angiogenesis. FASEB J. 2003;17:2103-2105.
23. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res. 2006;12:1665-1671.
24. Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266:4029-4032.
25. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445:177-182.
26. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004;64:7156-7168.
27. Vigneswaran N, Wu J, Sacks P, Gilcrease M, Zacharias W. Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. J Oral Pathol Med. 2005;34:77-86.
28. Wang WS, Chen PM, Hsiao HL, Ju SY, Su Y. Overexpression of the thymosin β-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene. 2003;22:3297-3306.
29. Wang WS, Chen PM, Hsiao HL, Wang HS, Liang WY, Su Y. Overexpression of the thymosin β-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma. Oncogene. 2004;23:6666-6671.
30. Xing RH, Rabbani SA. Regulation of urokinase production by androgens in human prostate cancer cells: effect on tumor growth and metastases in vivo. Endocrinology. 1999;140:4056-4064.
31. Yamamoto T, Gotoh M, Kitajima M, Hirohashi S. Thymosin β-4 expression is correlated with metastatic capacity of colorectal carcinomas. Biochem Biophys Res Commun. 1993;193:706-710.
32. Yoshioka S, Takahashi Y, Okimura Y, Takahashi K, Iguchi G, Iida K, Kaji H, Chihara K. Gene expression profile in the heart of spontaneous dwarf rat: in vivo effects of growth hormone. Biochem Biophys Res Commun. 2006;341:88-93.